Mycobacterium tuberculosis
Resistant to isoniazid and rifampicin
GRAM estimates the global prevalence of Mycobacterium tuberculosis complex infections with observed single- and multi-drug resistance to isoniazid and rifampicin. Based on a statistical analysis using data obtained from the WHO, findings are due for release in 2023.